Medical Necessity of Xiaflex for Peyronie's Disease

Patient Evaluation and Criteria Assessment

The patient presents with a significant penile curvature, which falls within the FDA-approved indication range of ≥30° and <90°, and has a palpable plaque confirmed on physical examination, meeting the required criteria for Xiaflex treatment 1, 2
The patient maintains intact erectile function, meeting another essential criterion for Xiaflex therapy, and exceeds the minimum age requirement of 18 years for this treatment 1

The American Urological Association (AUA) guidelines provide a moderate recommendation (Evidence Strength Grade B) for intralesional collagenase clostridium histolyticum in combination with modeling for patients with stable Peyronie's disease with curvature between 30° and 90° 1, 3
The treatment is being administered by a urologist who specializes in urological diseases, meeting the requirement that the provider be experienced in urological disease treatment 1

The documented treatment follows the FDA-approved protocol with proper dosing of 0.58 mg per injection administered into the Peyronie's plaque, and includes both clinician-administered injections and patient-performed modeling exercises as recommended in the treatment guidelines 1, 2, 3
The plan includes appropriate spacing between treatment cycles (6 weeks), consistent with guideline recommendations 1, 2

Clinical trials demonstrated that Xiaflex treatment results in mean curvature reduction of 17° compared to 9.3° with placebo at one-year follow-up, and can meaningfully impact sexual function and quality of life for patients with significant curvature 3, 4

The patient should be counseled about potential adverse events, including penile ecchymosis, swelling, pain, and rare but serious complications like corporal rupture, and most adverse events were mild to moderate and resolved without intervention 1, 3

If curvature decreases to less than 15° after treatment cycles, subsequent cycles should not be administered, and the safety of more than one treatment course has not been established 1
Patients should be advised that while Xiaflex can improve curvature, the average improvement is modest (approximately 17°), and some patients may still have residual curvature requiring additional interventions 3, 4